Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Faroux

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2016
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patientsThomas Aparicio, Dany Gargot, Laurent Teillet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
United European Gastroenterology Journal|April 14, 2017
Middle-term mortality and re-bleeding after initial diverticular bleeding: A nationwide study of 365 mostly elderly French patientsDiane Lorenzo, Claire Gallois, Pierre Lahmek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III StudyJulien Edeline, Meher Benabdelghani, Aurélie Bertaut, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|November 10, 2020
Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focusJean-Philippe Metges, Jean-Yves Douillard, Jean-François Ramée, et al.
Gut|May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumabAnthony Dohan, Benoit Gallix, Boris Guiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III TrialThierry André, Dewi Vernerey, Laurent Mineur, et al.
The New England Journal of Medicine|December 22, 2018
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Pascal Hammel, Mohamed Hebbar, et al.
Clinics and Research in Hepatology and Gastroenterology|December 12, 2018
Increased incidence of Campylobacter enteritis and their quinolone resistance between 2010 and 2015: Results of a French national observatory conducted in 21 general hospitals (CHG)Marie Trompette, Laura Le Guilloux, Laurent Souply, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2016
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patientsThomas Aparicio, Dany Gargot, Laurent Teillet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
United European Gastroenterology Journal|April 14, 2017
Middle-term mortality and re-bleeding after initial diverticular bleeding: A nationwide study of 365 mostly elderly French patientsDiane Lorenzo, Claire Gallois, Pierre Lahmek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III StudyJulien Edeline, Meher Benabdelghani, Aurélie Bertaut, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|November 10, 2020
Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focusJean-Philippe Metges, Jean-Yves Douillard, Jean-François Ramée, et al.
Gut|May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumabAnthony Dohan, Benoit Gallix, Boris Guiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III TrialThierry André, Dewi Vernerey, Laurent Mineur, et al.
The New England Journal of Medicine|December 22, 2018
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Pascal Hammel, Mohamed Hebbar, et al.
Clinics and Research in Hepatology and Gastroenterology|December 12, 2018
Increased incidence of Campylobacter enteritis and their quinolone resistance between 2010 and 2015: Results of a French national observatory conducted in 21 general hospitals (CHG)Marie Trompette, Laura Le Guilloux, Laurent Souply, et al.
Pageof 5